Are You Actually Low Risk for Heart Attack and Stroke?

Heart disease remains the leading cause-of-death category in the United States, and stroke remains a major cause of death and disability. Yet prevention is often reduced to one question: “What is my LDL?”

This is Part 1 of a four-part series: what to measure, what lifestyle can fix, what actually lowers persistent ApoB/LDL, and what risk can remain even when cholesterol looks great.

Before deciding what to change, you need to know what you are trying to change.

A standard lipid panel is still useful. LDL-C matters. Triglycerides matter. Non-HDL-C, calculated from the same panel, captures cholesterol carried by all ApoB-containing particles.

But two people with the same LDL-C can still have very different ASCVD risk, meaning risk from atherosclerotic cardiovascular disease, which includes heart attacks and many ischemic strokes. 

Blood pressure, smoking, diabetes and metabolic health, kidney function, age, family history and body composition all change the picture. That is why the 2026 cardiovascular guidelines moved toward PREVENT-ASCVD, a risk calculator that combines several of these domains instead of treating LDL-C as the diagnosis. It is designed for adults 30 to 79 without known cardiovascular disease, and a 2026 external validation in more than 680,000 people found good performance across 30 U.S. health systems. [1,2]

The practical point is simple: know your cholesterol, but interpret it inside your overall risk.

LDL-C, or low-density lipoprotein cholesterol, measures how much cholesterol is being carried inside LDL particles. ApoB, or apolipoprotein B, gives you a closer approximation of how many atherogenic particles are circulating. 

That distinction matters when the two disagree.

A 2025 review covering more than 590,000 people found that when ApoB and LDL-C disagreed, ApoB was the better predictor of cardiovascular risk in all nine direct comparisons. Genetic evidence also supports ApoB-containing particle burden as a causal part of atherosclerosis rather than simply a marker that appears after disease begins. [3,4]

Current U.S. guidelines still recommend ApoB selectively. I think one baseline ApoB is reasonable for a proactive adult if it is easy to access, then repeat mainly when it is elevated, disagrees with LDL-C, or you are tracking an intervention.

That is a MED Report synthesis, not universal guideline consensus.

Lipoprotein(a), or Lp(a), pronounced ‘L-P little a,’ is different. It is mostly inherited, changes relatively little over adulthood, and is not usually included in a standard cholesterol panel. 

Current guidelines recommend measuring it at least once in adulthood. [1]

There is also an important new caveat. On September 4, Novartis reported that its new Lp(a)-lowering drug, pelacarsen, substantially lowered Lp(a) in a large phase 3 trial but did not reduce heart attacks, strokes, or other major cardiovascular events overall. [5]

Because the company developing the drug had every incentive for a positive outcome, that negative result deserves weight. It weakens the claim that lowering Lp(a) is already a proven treatment strategy, but it does not erase its value as inherited risk information.

So for now: know it once. Do not constantly optimize it.

You may have heard the analogy that LDL is like firefighters at a fire: the firefighters are present, but inflammation caused the fire, not the firefighters.

The analogy goes too far.

Inflammation clearly matters. Some anti-inflammatory trials reduced events without lowering LDL, while others failed. C-reactive protein (CRP) appears to be more of a marker than the single cause of atherosclerosis. Genetic evidence still supports cumulative ApoB-particle exposure as causal. [4,6]

This is not cholesterol versus inflammation. They interact.

For screening, that means hsCRP can be useful when there is a reason to look for residual inflammatory risk, but I would not make it a mandatory annual test for everyone. It is nonspecific and can rise from infection, injury or even unusual recent exertion.

Some studies in very old adults show lower cholesterol associated with higher mortality. That finding is real, but it does not prove high cholesterol becomes protective.

Cholesterol often falls with frailty, illness, weight loss and in the years approaching death. Randomized evidence in adults 75 and older still shows fewer major vascular events when LDL is lowered. [7,8]

After about 75, especially with frailty or limited life expectancy, decisions should become more individualized. That is different from saying high LDL becomes beneficial.

This is where the gap becomes practical.

Blood pressure, glucose and a standard lipid panel are routine. ApoB and Lp(a) often are not. In a national database covering hundreds of millions of records, only about 0.24% of patients had Lp(a) measured in 2024. Other U.S. data also show ApoB testing remains uncommon. [9]

That does not mean your doctor is doing something wrong. A routine annual physical and a proactive cardiovascular risk assessment are simply not always the same thing. You may need to ask.

I also checked the funding problem rather than simply copying professional-society guidance.

The American Heart Association reported about $69.8 million from pharmaceutical, biotech and device manufacturers in fiscal 2024-25, roughly 5% of revenue. Meta-research also finds industry-sponsored studies more likely to report favorable conclusions. [10,11]

That does not make the guideline wrong. It means treatment claims deserve independent cross-checking. The case for ApoB-containing particles also comes from genetics, discordance studies and negative trials, not only drug-company research.

A normal-looking cholesterol panel does not prove you are low risk. But the answer is not to order every advanced test available.

The highest-value strategy is to cover the major pathways, then add selected tests only when they can change a decision.

For a proactive adult without known cardiovascular disease, I would use four buckets:

If you are 30 to 79 and do not already have cardiovascular disease, plug these numbers into the American Heart Association’s PREVENT calculator to estimate your 10-year and, when applicable, 30-year cardiovascular risk rather than interpreting LDL-C alone. [1,12]

Next in Part 2 (Edition #023): how much can a small set of lifestyle changes improve these risk factors at the same time?

Subscribe free — one edition in your inbox every Wednesday. No spam. No conflicts of interest. Any future sponsorships will be clearly disclosed and personally vetted.

After subscribing, check your junk/spam folder for the confirmation email and mark it as ‘Not Spam’ to ensure delivery.

1. Blumenthal RS, et al. 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001423

2. Khan SS, et al. External Validation of the PREVENT Equations in a National U.S. Sample. Circ Cardiovasc Qual Outcomes. 2026. https://pubmed.ncbi.nlm.nih.gov/42554063/

3. Sniderman AD, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. Systematic review. 2025. https://pubmed.ncbi.nlm.nih.gov/40681368/

4. Ference BA, et al. Association of genetic variants related to LDL-C, triglycerides, and ApoB with coronary heart disease. JAMA. 2019. https://jamanetwork.com/journals/jama/fullarticle/2722770

5. Novartis. Lp(a)HORIZON Phase III topline results. September 4, 2026. https://www.novartis.com/news/media-releases/novartis-announces-lpahorizon-phase-iii-topline-results-pelacarsen-patients-elevated-lpa-and-established-cardiovascular-disease-cvd

6. Kofler T, et al. C-reactive protein and cardiovascular risk in the general population. 2025. https://pubmed.ncbi.nlm.nih.gov/41378999/

7. Ravindrarajah R, et al. Trajectory of Total Cholesterol in the Last Years of Life Over Age 80 Years. J Gerontol A. 2017. https://pubmed.ncbi.nlm.nih.gov/29028914/

8. Gencer B, et al. Efficacy and safety of lowering LDL cholesterol in older patients: systematic review and meta-analysis of randomized controlled trials. Lancet. 2020. https://pubmed.ncbi.nlm.nih.gov/33186535/

9. Lipoprotein(a) Testing Trends in the United States 2015-2024: An Analysis of 300 Million Individuals. https://pmc.ncbi.nlm.nih.gov/articles/PMC12495319/

10. American Heart Association. Financial information and pharmaceutical, biotech and device manufacturer support, FY2024-2025. https://www.heart.org/en/about-us/american-heart-association-financial-information

11. Lundh A, et al. Industry sponsorship and research outcome: systematic review with meta-analysis. https://pubmed.ncbi.nlm.nih.gov/30132025/

12. AHA/ACC/ADA/ASN. 2026 Guideline for Cardiovascular-Kidney-Metabolic Syndrome. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001453

13. American College of Cardiology. CorCal Outcomes trial report. August 31, 2026. https://www.acc.org/latest-in-cardiology/articles/2026/08/29/08/48/mon-730am-corcal-evaold-isoleds-esc-2026